The market for diabetes and weight-loss drugs is set for a transformation starting Friday as Danish drugmaker Novo Nordisk’s patent on semaglutide expires, triggering the launch of a multitude of cheaper generic versions.Experts warned of potential misuse of weight loss drugs and the importance of medical supervision in their use for obesity and diabetes management. (Shutterstock)More than 50 branded versions of semaglutide, the active ingredient in Novo’s diabetes drug Ozempic and weight-loss treatment Wegovy are expected to enter the Indian market, making it one of the most crowded drug launches in recent years. The influx is likely to sharply reduce…